Lavinia Vija Racaru

Dr. Lavinia Vija Racaru


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 May 2023 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
MTMarie Terroir
Marie Terroir
CLChloé Lamesa
Chloé Lamesa
MKMehdi Krim
Mehdi Krim
LRLavinia Vija Racaru
Lavinia Vija Racaru
JTJean-Sébastien Texier
Jean-Sébastien Texier
FCFrédéric Courbon
Frédéric Courbon
Salivary gland cancers are rare tumors comprising a large group of heterogeneous tumors with variable prognosis. Their therapeutic management at a metastatic stage is challenging due to the lack of therapeutic lines and the toxicity of treatments. [177Lu]Lu-PSMA-617 (prostate-specific membrane antigen) is a vectored radioligand therapy (RLT) initially developed to treat castration-resistant metastatic prostate cancer with encouraging results in terms of efficacy and toxicity. Many malignant cells could be treated with [177Lu]Lu-PSMA-617 as long as they express PSMA as a consequence of androgenic pathway activation. RLT may be used when anti-androgen hormonal treatment has failed, particularly in prostate cancer. [177Lu]Lu-PSMA-617 has been proposed in certain salivary gland cancers, though the expression of PSMA is demonstrated by a significant uptake using [68Ga]Ga-PSMA-11 PET scan. This theranostic approach could be a new therapeutic option, warranting prospective investigation in a larger cohort. We review the literature on this subject and offer a clinical illustration of compassionate use in France as a perspective for administering [177Lu]Lu-PSMA-617 in salivary gland cancer.

Verified
Journal Article
Open access
PDF file
LRLavinia Vija Racaru
Lavinia Vija Racaru
Thyroid disorders (comprising thyroid dysfunctions such as hypo- or hyperthyroidism and thyroid cancer) are among the most common endocrine pathologies